Squamous cell carcinomas of the head and neck (SCC-HN) make up about 90% of all head and neck cancers (HNC). They are malignant tumours arising in various regions including oral cavity, larynx (throat) and pharynx. It can also include cancer of the salivary glands, sinuses, muscles or nerves in the head and neck, but these types of cancer are much less common.
SCC-HN are the seventh most common cancer diagnosis worldwide. They can arise due to a variety of aetiologic factors including tobacco-exposure, alcohol consumption and high-risk human papilloma virus (HPV) infection. Clinical outcomes and treatments vary by anatomic site with 5-year survival rates ranging from 40-80% depending on stage, subsite, and HPV status (1).
At CancerTools.org, we have created an ever-growing collection of HNC research tools, including patient-derived cell lines, which offer in vitro models for specific SCC-HN anatomical sites and antibodies for studying HNC biology.
Our collection also features antibodies to support HNC research, including those for HPV, as HPV status is a favourable indicator of prognosis in some subsets of HNC. As well as antibodies for p53 and EGFR, as overexpression of EGFR and inhibition of p53 are commonly observed in HPV-negative SCC-HN.
